This HTML5 document contains 131 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n25http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00279/identifier/guide-to-pharmacology/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00279/identifier/national-drug-code-directory/
n10http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n21http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/drugbank/dosage/
n6http://linked.opendata.cz/resource/drugbank/mixture/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00279/identifier/chemspider/
n33http://linked.opendata.cz/resource/drugbank/drug/DB00279/identifier/chebi/
n18http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n32http://linked.opendata.cz/resource/drugbank/drug/DB00279/identifier/wikipedia/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00279/identifier/pharmgkb/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00279/identifier/pdb/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00279/identifier/kegg-compound/
n19http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n20http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n31http://linked.opendata.cz/resource/drugbank/drug/DB00279/identifier/bindingdb/
n8http://www.drugs.com/cdi/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00279/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00279/identifier/pubchem-substance/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00279/identifier/iuphar/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00279/identifier/drugbank/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00279
rdf:type
n3:Drug
n3:description
The L-triiodothyronine (T3, liothyronine) thyroid hormone is normally synthesized and secreted by the thyroid gland in much smaller quantities than L-tetraiodothyronine (T4, levothyroxine, L-thyroxine). Most T3 is derived from peripheral monodeiodination of T4 at the 5 position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. [PubChem]
n3:dosage
n26:271B4727-363D-11E5-9242-09173F13E4C5 n26:271B4728-363D-11E5-9242-09173F13E4C5 n26:271B4729-363D-11E5-9242-09173F13E4C5 n26:271B472A-363D-11E5-9242-09173F13E4C5 n26:271B472B-363D-11E5-9242-09173F13E4C5 n26:271B472C-363D-11E5-9242-09173F13E4C5 n26:271B472D-363D-11E5-9242-09173F13E4C5 n26:271B472E-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, Anders MW, Endou H: Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol. 2002 Apr;61(4):729-37. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11901210
n3:group
approved
n3:halfLife
2.5 days
n3:indication
Used as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyrodism during the recovery phase of subacute thyroiditis.
n3:manufacturer
n5:271B4715-363D-11E5-9242-09173F13E4C5 n5:271B4716-363D-11E5-9242-09173F13E4C5 n5:271B4719-363D-11E5-9242-09173F13E4C5 n5:271B471A-363D-11E5-9242-09173F13E4C5 n5:271B4717-363D-11E5-9242-09173F13E4C5 n5:271B4718-363D-11E5-9242-09173F13E4C5
owl:sameAs
n12:DB00279 n18:DB00279
dcterms:title
Liothyronine
adms:identifier
n15:46506352 n16:5920 n17:39822-0151-1 n22:T3 n23:2634 n24:C02465 n27:2634 n28:5707 n29:DB00279 n30:PA164778866 n31:18860 n32:Liothyronine n33:18258
n3:mechanismOfAction
The hormones, T<sub>4</sub> and T<sub>3</sub>, are tyrosine-based hormones produced by the thyroid gland. Iodine is an important component in their synthesis. The major form of thyroid hormone in the blood is thyroxine (T4). This is converted to the more active liothyronine form by deiodinases in peripheral tissues. Liothyronine acts on the body to increase the basal metabolic rate, affect protein synthesis and increase the body's sensitivity to catecholamines (such as adrenaline). The thyroid hormones are essential to proper development and differentiation of all cells of the human body. To various extents T<sub>4</sub> and T<sub>3</sub> regulate protein, fat and carbohydrate metabolism. Their most pronounced effect is on how human cells use energetic compounds. The thyroid hormone derivatives bind to the thyroid hormone receptors initially to initiate their downstream effects.
n3:packager
n5:271B4709-363D-11E5-9242-09173F13E4C5 n5:271B470A-363D-11E5-9242-09173F13E4C5 n5:271B4707-363D-11E5-9242-09173F13E4C5 n5:271B4708-363D-11E5-9242-09173F13E4C5 n5:271B470D-363D-11E5-9242-09173F13E4C5 n5:271B470E-363D-11E5-9242-09173F13E4C5 n5:271B470B-363D-11E5-9242-09173F13E4C5 n5:271B470C-363D-11E5-9242-09173F13E4C5 n5:271B4701-363D-11E5-9242-09173F13E4C5 n5:271B4702-363D-11E5-9242-09173F13E4C5 n5:271B46FF-363D-11E5-9242-09173F13E4C5 n5:271B4700-363D-11E5-9242-09173F13E4C5 n5:271B4705-363D-11E5-9242-09173F13E4C5 n5:271B4706-363D-11E5-9242-09173F13E4C5 n5:271B4703-363D-11E5-9242-09173F13E4C5 n5:271B4704-363D-11E5-9242-09173F13E4C5 n5:271B4711-363D-11E5-9242-09173F13E4C5 n5:271B4712-363D-11E5-9242-09173F13E4C5 n5:271B470F-363D-11E5-9242-09173F13E4C5 n5:271B4710-363D-11E5-9242-09173F13E4C5 n5:271B4713-363D-11E5-9242-09173F13E4C5 n5:271B4714-363D-11E5-9242-09173F13E4C5 n5:271B46FD-363D-11E5-9242-09173F13E4C5 n5:271B46FE-363D-11E5-9242-09173F13E4C5
n3:synonym
Tertroxin Liothyronine 3,3',5-triiodo-L-thyronine O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine L-3,5,3'-Triiodothyronine Triiodothyronine 3,5,3'-Triiodothyronine Liotironina Liothyroninum 3,5,3'-Triiodo-L-thyronine Tresitope T3 3,5,3'TRIIODOTHYRONINE L-T3 4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine
n9:hasAHFSCode
n10:68-36-04
n3:mixture
n6:271B46FB-363D-11E5-9242-09173F13E4C5 n6:271B46FC-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
99.7%
n3:salt
n3:synthesisReference
Martin Beasley, David Hause, Irwin Klein, Charles Pamplin, David Reynolds, Kevin Sills, "Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same." U.S. Patent US20060246133, issued November 02, 2006.
n20:hasConcept
n21:M0021977
foaf:page
n8:liothyronine.html n25:liothyronine.htm
n3:IUPAC-Name
n4:271B4733-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4739-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4738-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4735-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4736-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4737-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4749-363D-11E5-9242-09173F13E4C5 n4:271B4731-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4732-363D-11E5-9242-09173F13E4C5 n4:271B474B-363D-11E5-9242-09173F13E4C5 n4:271B472F-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4730-363D-11E5-9242-09173F13E4C5 n4:271B474C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B473F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4740-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B473A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B473B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B473D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B473C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B473E-363D-11E5-9242-09173F13E4C5
n3:absorption
95% in 4 hours
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
6893-02-3
n3:category
n3:containedIn
n19:271B4724-363D-11E5-9242-09173F13E4C5 n19:271B4725-363D-11E5-9242-09173F13E4C5 n19:271B4722-363D-11E5-9242-09173F13E4C5 n19:271B4723-363D-11E5-9242-09173F13E4C5 n19:271B4726-363D-11E5-9242-09173F13E4C5 n19:271B471C-363D-11E5-9242-09173F13E4C5 n19:271B471D-363D-11E5-9242-09173F13E4C5 n19:271B471B-363D-11E5-9242-09173F13E4C5 n19:271B4720-363D-11E5-9242-09173F13E4C5 n19:271B4721-363D-11E5-9242-09173F13E4C5 n19:271B471E-363D-11E5-9242-09173F13E4C5 n19:271B471F-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4745-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4747-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4748-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B474A-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4744-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4743-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4746-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4734-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4741-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4742-363D-11E5-9242-09173F13E4C5